Gregory A. Bonfiglio

Gregory Bonfiglio
Mr. Bonfiglio was a Senior Partner with Anthem Venture Partners, a diversified, early stage venture fund in California, from 2000 – 2005.  Anthem invested in both IT and biotech companies, and Mr. Bonfiglio led the biotech investments.  Anthem invested in Corus Pharma, along with Burrill & Co.  Mr. Bonfiglio led the Corus investment and held the Corus Board seat.  Mr. Bonfiglio helped engineer the sale of Corus to Gilead in 2006.  Mr. Bonfiglio also led Anthem’s investment in Advanced Cell Technology in 2000, and helped take the company public in 2005.  Anthem generated top-quartile returns for its investors.

Mr. Bonfiglio has served on many company boards including Corus Pharma (inhaled aztreonam for cystic fibrosis); California Stem Cell (hESC tools & therapeutics); StemCyte, Inc. (cord blood storage & therapeutics); and VistaGen Therapeutics (in vitro tools from hESCs).  

Since forming Proteus in 2006, Mr. Bonfiglio has been focused on the field of Regenerative Medicine. Mr. Bonfiglio is the Chairman of the Board of the CCRM, a regenerative medicine translation center in Toronto, Canada. Mr. Bonfiglio speaks frequently at regenerative medicine conferences on finance and commercialization issues.  He is a Member of the ISSCR, and serves on their Finance Committee.   In 2013, Mr. Bonfiglio was ranked 14th in a list of the Top 50 Stem Cell Influencers in the world.

Mr. Bonfiglio received his B.A. in Mathematics (magna cum laude) from Michigan State University in 1975, and his J.D. (magna cum laude) from the University of Michigan Law School in 1981. He lives in Portola Valley, California, and is actively involved in the community.

Board Representation